Drugs / CT-P55
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT07054970 | Jan → Aug 2024 | — | Celltrion | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06630559 | May 2025 → Feb 2026 overdue | psoriasis | Celltrion | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Celltrion | Results Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025 celltrion.com ↗
To further its commitment to immunology, Celltrion presented an abstract for its proposed secukinumab biosimilar candidate, CT-P55 which demonstrated comparable efficacy and safety profiles to the reference secukinumab in healthy subjects.3 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Celltrion | Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025 celltrion.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTP55 | “Currently, there are no secukinumab biosimilars available to patients in the European Union (EU) or the United States (US), but a potential biosimilar called ‘CTP55’ is being developed.” PMID 41665131 ↗ Feb 2026 |
| Known as | secukinumab | “CT-P55 is a recombinant humanized monoclonal antibody containing the active ingredient secukinumab.” NCT06630559 ↗ |
| Modality | Monoclonal antibody | “CT-P55 is a recombinant humanized monoclonal antibody” NCT06630559 ↗ |
| Route | Subcutaneous | “2 subcutaneous (SC) injections” NCT06630559 ↗ |